Management of glia-mediated neuroinflammation and related patents

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 8, Issue 2, 2014, Pages 118-124

  Jha, Mithilesh Kumar ^a   Suk, Kyoungho ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Central nervous system; Glia; Gliosis; Inflammation; Neuroinflammation; Novel bioactive compounds

Indexed keywords

CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; GLIA; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROGENIC INFLAMMATION; NEUROTOXICITY SYNDROMES; PATENT; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; NEUROGENIC INFLAMMATION; NEUROGLIA; NEUROTOXICITY SYNDROMES; PATENTS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84905649915     PISSN: 1872213X     EISSN: 22122710     Source Type: Journal    
DOI: 10.2174/1872213X08666140619105915     Document Type: Review

References (100)

1. Breunig JJ, Guillot-Sestier MV, Town T. Brain injury, neuro- inflammation and Alzheimer's disease. Front Aging Neurosci 2013; 5: 26.
2. O'Callaghan JP, Sriram K, Miller DB. Defining neuro-inflammation. Ann N Y Acad Sci 2008; 1139: 318-330.
3. Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J 2014; 33(1): 7-22.
4. Ransohoff RM, Perry VH. Microglial physiology: Unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-145.
5. Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuro-inflammation: The role and consequences. Neurosci Res 2014; 79: 1-12.
6. Aguzzi A, Barres BA, Bennett ML. Microglia: Scapegoat, saboteur, or something else? Science 2013; 339(6116): 156-161.
7. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia 2013; 61(12):1939-1958.
8. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuro- inflammation: Partners in crime? Immunology 2013; 141(3): 314-327.
9. Gimsa U, Mitchison NA, Brunner-Weinzierl MC. Immune privilege as an intrinsic CNS property: Astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm 2013; 2013: 320519.
10. Craft JM, Watterson DM,Van Eldik LJ. Neuroinflammation: A potential therapeutic target. Expert Opin Ther Targets 2005; 9(5): 887-900.
11. Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009; 4(4): 419-429.
12. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv Neurol 2001; 86: 83-89.
13. More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm 2013; 2013: 952375.
14. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: Focus on astrocytes. Mol Neurobiol 2013; 49(1): 28-38.
15. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43(4): 225-232.
16. Farooqui T, Farooqui AA. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinsons Dis 2011; 2011: 247467.
17. Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of abeta1-42-induced Alzheimer's disease model rats. PLoS One 2013; 8(10): e75786.
18. Costa G, Frau L, Wardas J, Pinna A, Plumitallo A, Morelli M. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord 2013; 28(14): 1957-1965.
19. Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1beta and tumor necrosis factor-alpha: Reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci 2013; 7: 53.
20. Ubogu EE. Translational strategies in peripheral neuro-inflammation and neurovascular repair. Transl Neurosci 2012; 3(4): 373-383.
21. Niranjan R. Molecular basis of etiological implications in Alzheimer's disease: Focus on neuroinflammation. Mol Neurobiol 2013; 48(3): 412-428.
22. Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 2012; 60(4): 251-266.
23. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl 1): S210-S212.
24. Deslauriers AM, Afkhami-Goli A, Paul AM, Bhat RK, Acharjee S, Ellestad KK, et al. Neuroinflammation and endoplasmic reticulum stress are coregulated by crocin to prevent demyelination and neurodegeneration. J Immunol 2011; 187(9): 4788-4799.
25. Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, et al. Neuroinflammation in Parkinson's disease: Is there sufficient evidence for mechanism-based interventional therapy? Front Biosci 2008; 13, 709-717.
26. Chung YC, Kim YS, Bok E, Yune TY, Maeng S, Jin BK. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm 2013; 2013: 370526.
27. Milena ZA, Zeitelhofer M, Eriksson U, Olsson T, Nilsson I. Correction: Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One 2013; 8(6):DOI:10.1371/annotation/dd60f248-ca3f-4824-a3b4-c07aefb1c7c3.
28. Steelman AJ, Smith R, Welsh CJ, Li J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J Biol Chem 2013; 288(33): 23776-23787.
29. Morsali D, Bechtold D, Lee W, Chauhdry S, Palchaudhuri U, Hassoon P, et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 2013; 136(Pt 4): 1067-1082.
30. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuro-inflammation. Nat Commun 2012; 3: 1227.
31. Moller T. Neuroinflammation in Huntington's disease. J Neural Transm 2010; 117(8):1001-1008.
32. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012; 7(12): e52941.
33. Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013; 53: 34-41.
34. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol 2011; 10(3): 253-263.
35. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005; 76(2): 77-98.
36. McGeer EG, McGeer PL. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007; 21(10): 789-797.
37. Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson's disease: Neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006; 26(4-6): 781-802.
38. Rubio-Perez JM, Morillas-Ruiz JM. A review: Inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012; 2012: 756357.
39. Broussard GJ, Mytar J, Li RC, Klapstein GJ. The role of inflammatory processes in Alzheimer's disease. Inflammo-pharmacology 2012; 20(3): 109-126.
40. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21(3): 383-421.
41. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184(1-2): 69-91.
42. Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 2006; 12(9): 1005-1015.
43. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 2002; 72(2): 233-238.
44. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004; 5(6): 529-534.
45. Mrak RE,Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005; 26(3): 349-354.
46. Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: A position paper. Curr Alzheimer Res 2007; 4(2): 185-189.
47. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37(2): 289-305.
48. Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 2011; 286(5): 3693-3706.
49. Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh HS, Lee SC. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflam-matory miR-155 and miR-155;. Glia 2011; 59(12): 1911-1922.
50. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010; 58(1): 103-113.
51. Zheng LT, Hwang J, Ock J, Lee MG, Lee WH, Suk K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J Neurochem 2008; 107(5): 1225-1235.
52. Ramirez G, Rey S, von Bernhardi R. Proinflammatory stimuli are needed for induction of microglial cell-mediated AbetaPP_{244-C} and Abeta-neurotoxicity in hippocampal cultures. J Alzheimers Dis 2008; 15(1): 45-59.
53. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007; 4: 21.
54. Di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M, Errea O, et al. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 2013; 8(2): e54722.
55. He FQ, Qiu BY, Li TK, Xie Q, Cui De J, Huang XL, et al. Tetrandrine suppresses amyloid-beta-induced inflammatory cytokines by inhibiting NF-kappaB pathway in murine BV2 microglial cells. Int Immunopharmacol 2011; 11(9): 1220-1225.
56. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in vitro model of brain inflammation. J Neuroinflammation 2010; 7: 30.
57. Coleman M. Axon degeneration mechanisms: Commonality amid diversity. Nat Rev Neurosci 2005; 6(11): 889-898.
58. Coleman MP, Perry VH. Axon pathology in neurological disease: A neglected therapeutic target. Trends Neurosci 2002; 25(10): 532-537.
59. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58(4): 495-505.
60. Su KG, Banker G, Bourdette D, Forte M. Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009; 9(5): 411-417.
61. Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: Implications in Alzheimer's disease. J Neuroimmunol 2000; 105(2): 124-130.
62. Fan MM, Raymond LA. N-Methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007; 81(5-6): 272-293.
63. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66(11): 1638-1643.
64. Kalonia H, Kumar P, Kumar A. Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. Brain Res 2011; 1372: 115-126.
65. Ellrichmann G, Reick C, Saft C, Linker RA. The role of the immune system in Huntington's disease. Clin Dev Immunol 2013; 2013: 541259.
66. Zadori D, Klivenyi P, Szalardy L, Fulop F, Toldi J, Vecsei L. Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci 2012; 322(1-2): 187-191.
67. Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum Mol Genet 2013; 22(9): 1826-1842.
68. Yamada J, Jinno S. Alterations in neuronal survival and glial reactions after axotomy by ceftriaxone and minocycline in the mouse hypoglossal nucleus. Neurosci Lett 2011; 504(3): 295-300.
69. Kraft AD, Kaltenbach LS, Lo DC, Harry GJ. Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol Aging 2012; 33(3): 621-633.
70. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Hum Brain Mapp 2011; 32(2): 258-270.
71. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009; 132(Pt 11): 3152-3164.
72. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26(4): 459-470.
73. Weydt P, Yuen EC, Ransom BR, Moller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004; 48(2): 179-182.
74. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009; 72(1): 14-19.
75. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23(3): 249-256.
76. Weydt P, Weiss MD, Moller T, Carter GT. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs 2002; 3(12): 1720-1724.
77. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15(3): 601-609.
78. Anneser JM, Chahli C, Ince PG, Borasio GD, Shaw PJ. Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2004; 63(8): 831-840.
79. Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 2012; 237(1): 147-152.
80. Valente T, Mancera P, Tusell JM, Serratosa J, Saura J. C/EBPbeta expression in activated microglia in amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33(9): 2186-2199.
81. Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol 2011; 30(1): 4-8.
82. Lee M, Kwon BM, Suk K, McGeer E, McGeer PL. Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage. J Neuroimmune Pharmacol 2012; 7(1): 173-186.
83. Vizcaychipi MP, Watts HR, O'Dea KP, Lloyd DG, Penn JW, Wan Y, et al. The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline. Ann Surg 2014; 259(6):1235-1244.
84. Shin, S.Y., Lee, Y.H., Koh, D.S., Lim, Y.H. Pharmaceutical composition including a diphenylpropenone compound as an active ingredient for preventing and treating an inflammatory disorder in the nervous system. WO2013065922 (2013).
85. Huang, Z., Zhou, G. Benzimidazole derivatives, pharmaceutical composition in which these derivatives are comprised and use thereof for the preparation of medicaments. CZ0303726 (2013).
86. Wulff, H., Jin, L.W., Maezawa, I. Reduction of microglia-mediated neurotoxicity by kv1.3 inhibition. WO2013170917 (2013).
87. Booth, R. Cathepsin inhibitors for treating microglia mediated neuron loss in the central nervous system. US20120329837 (2012); EP2720692 (2014).
88. Sho, E. Protein kinase C-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation. US20130012447 (2013).
89. Jiang, X., Greiner, J., Maravetz, L.L., Szucs, S.S., Visnick, M. Antioxidant inflammation modulators: Novel derivatives of oleanolic acid. US8338618 (2013).
90. Hall, A., Farthing, C.N., Pineiro, J.L.C. Fused amino-dihydrothiazine derivatives. US8338407 (2013).
91. Giulian, D.J. Methods for diagnosis and monitoring of neurological disease by detection of an excephalotoxin. US8334100 (2013).
92. Tykocinski, M.L., Razmara, M. Fn14/TRAIL fusion proteins and method of treating cancer. US8329657 (2013).
93. Honda, T., David, E., Mierke, D. Monocyclic cyanoenones and methods of use thereof. US8314137 (2012).
94. Muto, S., Nagano, T., Sotome, T., Itai, A. Inhibitors against the production and release of inflammatory cytokines. US8263657(2012).
95. Pfeifer, A., Pihlgren, M., Muhs, A., Watts, R. Methods of treating amyloidosis with humanized anti-beta-amyloid antibodies. US8246954 (2012).
96. Pert, C., Ruff, M. Modified peptide that reduces pain in peripheral neuropathy. WO2012109464 (2012).
97. Maccioni, R. Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound. US8198300 (2012).
98. Watterson, M., Van Eldik, L., Hu, W. Compositions and treatments using pyridazine compounds and cholinesterase inhibitors. US8158627 (2012).
99. Tobinick, E.L. Cytokine antagonists for neurological and neuropsychiatric disorders. US8119127 (2012).
100. Maze, M., Feldman, M., Terrando, N., Cibelli, M., Ma, D.,Fertleman, M. Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist. WO2011101634 (2011).